Daniel Richardson is a former Senior District Business Manager for Bristol-Myers Squibb (BMS). Richardson prevailed in one of the largest qui tam whistleblower cases filed against a major pharmaceutical company for “off label” marketing and illegal kickbacks. Richardson, in conjunction with other whistleblowers, held BMS accountable under the False Claims Act.
Based on frauds primarily related to federal and state Medicare and Medicaid programs, the company had to pay $515 million in fines and penalties. The whistleblowers, including Mr. Richardson, obtained their mandatory qui tam whistleblower rewards, once again demonstrating how the whistleblower reward laws are the most powerful tool for holding fraudsters accountable.